Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients

BACKGROUND AND AIMS: The majority of patients treated with anti-tumor necrosis factor (TNF) therapy develop anti-drug antibodies (ADAs), which might result in loss of treatment efficacy. Strict guidelines on measuring trough levels (TLs) and ADA in clinical routine do not exist. To provide real-worl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Inflamm Intest Dis
Autors principals: Reinhold, Ilana, Blümel, Sena, Schreiner, Jens, Boyman, Onur, Bögeholz, Jan, Cheetham, Marcus, Rogler, Gerhard, Biedermann, Luc, Scharl, Michael
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8015259/
https://ncbi.nlm.nih.gov/pubmed/33850838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000511296
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars